Mai Capital Management Contrafect Corp Transaction History

Mai Capital Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	BUY	$2.79 - $4.45 $681,853 - $1.09 Million	244,392 Added 2125.15%	255,892 $786,000
Q2 2021 Jul 19, 2021	SELL	$3.58 - $4.9 $35,800 - $49,000	-10,000 Reduced 46.51%	11,500 $51,000
Q1 2021 May 10, 2021	BUY	$4.46 - $6.68 $95,890 - $143,620	21,500 New	21,500 $103,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.